U.S. Capital Wealth Advisors, LLC Aldeyra Therapeutics, Inc. Transaction History
U.S. Capital Wealth Advisors, LLC
- $3.03 Billion
- Q4 2024
A detailed history of U.S. Capital Wealth Advisors, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, U.S. Capital Wealth Advisors, LLC holds 13,875 shares of ALDX stock, worth $81,723. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,875Holding current value
$81,723% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
119Shares Held
36.7MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$54.6 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$32.3 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$22.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$21.3 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$11.1 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $344M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...